Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 51.87M | 90.98M | 164.31M | 320.52M | 326.25M |
Gross Profit | -58.61M | -90.44M | -48.91M | 32.33M | 9.02M |
EBITDA | -147.20M | -110.08M | 7.21M | 77.60M | 87.68M |
Net Income | -139.24M | -93.08M | -97.75M | -59.23M | -36.13M |
Balance Sheet | |||||
Total Assets | 609.51M | 799.30M | 968.02M | 1.11B | 1.21B |
Cash, Cash Equivalents and Short-Term Investments | 19.51M | 47.71M | 71.68M | 92.92M | 167.68M |
Total Debt | 438.22M | 408.17M | 400.51M | 390.77M | 426.25M |
Total Liabilities | 519.30M | 512.25M | 547.21M | 593.43M | 633.58M |
Stockholders Equity | 601.22M | 764.05M | 851.21M | 917.48M | 954.27M |
Cash Flow | |||||
Free Cash Flow | -23.31M | -16.22M | -30.52M | -11.87M | 29.89M |
Operating Cash Flow | -22.13M | 2.48M | -21.22M | 3.04M | 38.44M |
Investing Cash Flow | -9.31M | -11.53M | 9.70M | -20.82M | -22.41M |
Financing Cash Flow | 7.26M | -14.69M | -6.16M | -53.95M | -19.61M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
51 Neutral | HK$161.38M | ― | -20.40% | ― | -42.99% | -49.34% | |
50 Neutral | HK$52.31M | 23.24 | 0.44% | ― | 11.02% | 79.24% | |
48 Neutral | HK$111.03M | 1.06 | ― | 10.19% | -91.08% | ||
44 Neutral | AU$1.45B | -6.10 | -40.74% | 3.82% | -3.45% | -41.76% | |
34 Underperform | HK$26.25M | 0.72 | ― | ― | ― | ||
23 Underperform | HK$164.35M | ― | -2832.88% | ― | -49.37% | -930.65% |
Greenheart Group Limited has announced amendments to its proposed rights issue, which will now proceed without an excess application arrangement. This change impacts the structure of the rights issue, affecting shareholders’ ability to apply for excess shares. The company has also set a detailed timetable for the rights issue process, with key dates including the last day of dealings in shares on a cum-rights basis on June 17, 2025, and the record date for determining entitlements on June 26, 2025.
Greenheart Group Limited has announced a proposed rights issue to raise up to HK$33,668,088 by offering one rights share for every two existing shares at a price of HK$0.0363 per share. The rights issue is not underwritten and will proceed irrespective of the level of acceptance, with any unsubscribed shares to be placed to independent placees on a best effort basis. Additionally, the company plans to change its board lot size for trading from 2,000 shares to 80,000 shares, effective July 9, 2025. This move is expected to impact trading liquidity and shareholder engagement.
Greenheart Group Limited has announced the establishment of a Nomination Committee, as resolved by its Board of Directors. The committee will consist of at least three members, with a majority being independent non-executive directors, and will include at least one member of a different gender. The creation of this committee is aimed at enhancing the governance structure of the company, potentially impacting its operational efficiency and stakeholder confidence.
Greenheart Group Limited held its Annual General Meeting on June 10, 2025, where all proposed resolutions were passed unanimously. Key resolutions included the approval of financial statements, re-election of directors, and granting mandates for share issuance and repurchase, indicating strong shareholder support and stable governance.
Greenheart Group Limited, a company listed on the Hong Kong Stock Exchange, has announced changes in its Nomination Committee effective June 10, 2025. The changes include the appointment of Ms. Suen Chung Yan, Julia as a member, the cessation of Mr. Cheng Chi-Him, Conrad as chairman and member, and the re-designation of Mr. To Chun Wai as the new chairman. These adjustments are part of the company’s ongoing efforts to strengthen its governance structure.
Greenheart Group Limited has announced the composition of its board of directors and their respective roles and functions. The board includes executive, non-executive, and independent non-executive directors, with specific members assigned to the Audit, Remuneration, and Nomination Committees, indicating a structured governance framework.